Search Results - "Gruppo, R."

Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program by Christopherson, Pamela A., Haberichter, Sandra L., Flood, Veronica H., Perry, Crystal L., Sadler, Brooke E., Bellissimo, Daniel B., Di Paola, Jorge, Montgomery, Robert R., Abshire, T, Weiler, H, Lillicrap, D, James, P, O’Donnell, J, Ng, C, Bennett, C, Sidonio, R, Manco‐Johnson, M, Journeycake, J, Zia, A, Lusher, J, Rajpurkar, M, Shapiro, A, Lentz, S, Gill, J, Leissinger, C, Ragni, M, Tarantino, M, Roberts, J, Hord, J, Strouse, J, Ma, A, Valentino, L, Boggio, L, Sharathkumar, A, Gruppo, R, Kerlin, B, Kulkarni, R, Green, D, Hoots, K, Brown, D, Mahoney, D, Mathias, L, Bedros, A, Diamond, C, Neff, A, DiMichele, D, Giardina, P, Cohen, A, Paidas, M, Werner, E, Matsunaga, A, Shafer, F, Konkle, B, Cuker, A, Kouides, P, Stein, D

“…Background Type 3 von Willebrand Disease (VWD) is a rare and severe form of VWD characterized by the absence of von Willebrand factor (VWF). Objectives As part…”
Get full text

Subcutaneous diphtheria and tetanus vaccines in children with haemophilia: A pilot study and review of the literature by Schaefer, B. A., Gruppo, R. A., Mullins, E. S., Tarango, C.

“…Introduction Subcutaneous (SQ) vaccination has emerged as standard of care in children with severe bleeding disorders to reduce unnecessary factor exposure and…”
Get full text

Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients by Brand, B., Gruppo, R., Wynn, T. T., Griskevicius, L., Lopez Fernandez, M. F., Chapman, M., Dvorak, T., Pavlova, B. G., Abbuehl, B. E.

“…Introduction BAX 855 is a pegylated full‐length recombinant factor VIII (rFVIII) with an extended half‐life, built on a licensed rFVIII (ADVATE®). BAX 855…”
Get full text

The use of a single von Willebrand factor‐containing, plasma‐derived FVIII product in hemophilia A immune tolerance induction: the US experience by KURTH, M., PUETZ, J., KOUIDES, P., SANDERS, J., SEXAUER, C., BERNSTEIN, J., GRUPPO, R., MANCO‐JOHNSON, M., NEUFELD, E. J., RODRIGUEZ, N., WICKLUND, B., QUON, D., ALEDORT, L.

“…Background: Inhibitors are a serious complication for patients with severe hemophilia A. Immune tolerance induction (ITI) is the primary method for eradicating…”
Get full text

Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE) by Gruppo, R. A., Kessler, C. M., Neufeld, E. J., Cooper, D. L.

“…Summary Recent data from the Dosing Observational Study in Hemophilia diary study has described home treatment with recombinant activated factor VII (rFVIIa)…”
Get full text

Patient/Caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE) by YOUNG, G., SHAPIRO, A. D., WALSH, C. E., GRUPPO, R. A., GUT, R. Z., COOPER, D. L.

“…Patients with congenital haemophilia with inhibitors experience acute bleeds managed with bypassing agents, such as recombinant FVIIa (rFVIIa). Home‐based…”
Get full text

Radionuclide synovectomy/synoviorthesis (RS) in persons with bleeding disorders: A review of impact of national guidance on frequency of RS using the ATHNdataset by Sharma, R., Dunn, A., Aschman, D., Cheng, D., Wheeler, A., Soni, A., McGuinn, C., Knoll, C., Stein, D. T., Young, G., French, J., Sanders, J., Davis, J. A., Tarantino, M., Lim, M., Gruppo, R., Sidonio, R., Ahuja, S., Carpenter, S., Pipe, S., Shapiro, A.

Get full text

Radionuclide synovectomy in patients with bleeding disorders: a review of malignancy and myeloproliferative neoplasms from the ATHNdataset by Lim, M. Y., Cheng, D., Aschman, D., Dunn, A., Ahuja, S, Carpenter, SL, Davis, JA, French, J, Gruppo, R, Knoll, C, McGuinn, C, Pipe, SW, Sanders, J, Shapiro, A, Sidonio, R, Soni, A, Stein, DT, Tarantino, MD, Paroskie, A, Young, G

Get full text

BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study by WINDYGA, J., RUSEN, L., GRUPPO, R., O'BRIEN, A. C., KELLY, P., ROTH, D. A, ARKIN, S.

“…Moroctocog alfa (AF‐CC) (Xyntha™, BDDrFVIII) is manufactured by a process designed to enhance the theoretical viral safety profile relative to ReFacto®, its…”
Get full text

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A by Tarantino, M. D., Collins, P. W., Hay, C. R. M., Shapiro, A.D., Gruppo, R. A., Berntorp, E., Bray, G. L., Tonetta, S. A., Schroth, P. C., Retzios, A. D., Rogy, S. S., Sensel, M. G., Ewenstein, B. M.

“…The efficacy and safety of an advanced category recombinant antihaemophilic factor produced by a plasma- and albumin-free method (rAHF-PFM) was studied in 111…”
Get full text

Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - a meta-analysis by Gruppo, R. A., Brown, D., Wilkes, M. M., Navickis, R. J.

“…Recently reported data suggest the possibility of differences in clinical efficacy between full‐length factor VIII (FL‐FVIII) and B‐domain deleted recombinant…”
Get full text

A Multicenter Study of Recombinant Factor VIII (Recombinate): Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients With Hemophilia A by Bray, G.L., Gomperts, E.D., Courier, S., Gruppo, R., Gordon, E.M., Manco-Johnson, M., Shapiro, A., Scheibel, E., III, G. White, Lee, M.

“…In July 1990, the Recombinate Study Group initiated a prospective, open-labeled investigation of recombinant factor VIII (r-FVIII) to assess its safety and…”
Get full text

Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII - a robust meta-analytic finding by Gruppo, R. A., Brown, D., Wilkes, M. M., Navickis, R. J.

“…Meta‐analyses of observational studies have become increasingly common to support evidence‐based clinical decisions. We analyzed currently available clinical…”
Get full text

Meta-analytic evidence of increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII by Gruppo, R. A., Brown, D., Wilkes, M. M., Navickis, R. J.

“…A recent meta‐analysis of 13 observational studies suggested reduced haemostatic efficacy during prophylaxis and shortened half‐life of B‐domain deleted factor…”
Get full text

Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation by MORRIS, J. D, HARRIS, R. E, HASHMI, R, SAMBRANO, J. E, GRUPPO, R. A, BECKER, A. T, MORRIS, C. L

“…A hypercoaguable state has been shown to follow high-dose chemotherapy for bone marrow transplantation (BMT). Deficiency of the natural anticoagulants,…”
Get full text

Secondhand smoke, hypofibrinolysis, and Legg-Perthes disease by Glueck, C J, Freiberg, R A, Crawford, A, Gruppo, R, Roy, D, Tracy, T, Sieve-Smith, L, Wang, P

“…In 39 children with Legg-Perthes disease who were nonsmokers, the specific aim was to assess relationships among parental cigarette smoking during pregnancy,…”
Get more information

Protein C deficiency related to valproic acid therapy: A possible association with childhood stroke by Gruppo, Ralph, DeGrauw, Antonius, Fogelson, Harold, Glauser, Tracy, Balasa, Vinod, Gartside, Peter

“…We report a case of stroke in a child with acquired protein C deficiency receiving valproic acid (VPA). To investigate the possible association of VPA with…”
Get full text

Prophylaxis for hemophilia: State of the art or state of confusion? by Gruppo, Ralph A.

“…J Pediatr 1998;132:915-7…”
Get full text

Legg-Perthes disease in three siblings, two heterozygous and one homozygous for the factor V Leiden mutation by Gruppo, Ralph, Glueck, Charles J., Wall, Eric, Roy, Dennis, Wang, Ping

“…A family is described with three-generation transmission of factor V Leiden (a thrombophilic mutation that causes resistance to activated protein C)…”
Get full text

The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults by Balasa, V V, Gruppo, R A, Glueck, C J, Stroop, D, Becker, A, Pillow, A, Wang, P

“…Studies in adults have demonstrated that the genetic mutations C677T methylenetetrahydrofolate reductase (MTHFR), prothrombin 20210A, and the 4G polymorphism…”
Get more information